Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for patients with severe and life-threatening diseases. Its products under development include EBV-CTL, which is Phase II clinical trials for the treatment of malignancies associated with Epstein Barr Virus (EBV), including EBV-associated post-transplant lymphoproliferative disorders; CMV-CTL that is in Phase II clinical trials for the treatment of cytomegalovirus (CMV); WT1-CTL, which is in Phase I clinical trial for the treatment of cancers expressing the antigen Wilms Tumor 1. The company is also developing STM 434, that is in Phase I clinical trial for the treatment of ovarian cancer and other solid tumors; and a pipeline of product candidates that are in preclinical development. It has research collaboration with Memorial Sloan Kettering Cancer Center to discover and develop T-cell product candidates. Atara Biotherapeutics, Inc. was founded in 2012 and is headquartered in South San Francisco, California.